Investor Relations

Latest News

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

View Press Release View All News

Latest Presentation

Corporate Overview

View Presentation View All Presentations

Upcoming Event

2023 Annual Meeting of Shareholders

View Event Add to Calendar View All Events

Latest Financial Results

Q1 2023

Quarter Ended Mar 31, 2023
Earnings Release
PDF HTML
10-Q Filing
PDF HTML
XBRL
ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Report Links

Company Overview

ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and Nasdaq (ticker symbol: PMN). ProMIS is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).

View Management Team View Board of Directors

Toronto, Canada Office

Address

1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Canada

Cambridge, MA U.S. Office

Address

Cambridge Innovation Center
1 Broadway
Cambridge, MA 02142
U.S.A.